Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... (HCV) and other viral pathogens, is capable of capturing exosomes secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. The ... Board of Exosome Sciences, Inc. (ESI). Dr. Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic. ESI, a wholly owned ...
2009 NOV 23 ... being conducted in Sweden on advanced-stage cancer patients with documented progressive solid tumors and no remaining treatment options. The first part of the trial has been ... so far was not designed to demonstrate efficacy, a number of patients show signs of tumor necrosis on PET (positron emission tomography). Targeting cancer cells with AXL1717 ...
2009 NOV 23 ... of Morningside. "OncoVEX is an extremely promising treatment for many hard to treat solid tumor types and we look forward to working with management to fully realize the potential of ...
2009 NOV 23 ... cancer is one of the most deadly forms of cancer and ranks as the fifth most common solid tumor cancer. The incidence of primary liver cancer is approximately 20,000 cases per year in ...
2009 NOV 23 ... Fleximer=AE platform. XMT-1001 is currently in a Phase 1 trial in patients with advanced solid tumors. Non-Fleximer-linked CPT was shown to be active in prior clinical studies ... demonstrated an improved therapeutic window compared to CPT or irinotecan in human tumor xenograft studies. The review also reports that XMT-1001, unlike many other conjugated ...
2009 NOV 23 ... antigen and has been described as a corepressor of retinoic acid signaling in solid tumor cells, but its function in hematopoietic cells is unknown." "PRAME mRNA ...
2009 NOV 23 ... autologous DCs have been conducted in patients with a number of hematological and solid cancers, including malignant melanoma, lymphoma, myeloma, and non-small cell lung ... States, "Effective cancer immunotherapy depends on the body's ability to generate tumor antigen-presenting cells and tumor-reactive effector lymphocytes. As the most potent ...
2009 NOV 23 ... to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors,' is now available. "The purpose of this study is to evaluate the improved ...
2009 NOV 23 ... as a distant metastatic lesion. We report a case of a 61-year-old woman presented with a solid mass located in the left temporo-occipital region." "The 3D computed ... underwent surgery where a soft mass with transverse sinus invasion was encountered, the tumor was successfully resected employing microsurgical techniques. Histological examination ...
2009 NOV 23 ... published their study in Nature Reviews Clinical Oncology (Molecular imaging of solid tumors: exploiting the potential. Nature Reviews Clinical Oncology, 2009;6(10):609-611). ... administered over long periods of time, and result in disease stabilization rather than tumor shrinkage." "The activity of these novel agents might, therefore, be ...
2009 NOV 23 ... a compound with low micromolar cytotoxicity against a wide-range of hematologic and solid tumor cells. More excitingly, our studies of 5q in camptothecin (CCRF-CEM/C2) and mitoxantrone ...
2009 NOV 24 ... for how nonspherical carriers deliver both imaging agents and anticancer therapeutics to solid tumors." Christian and colleagues published their study in Molecular ... "NIRF imaging further suggests that filomicelles convect into a tumor and some fragments can penetrate into the tumor stroma. To assess a functional effect, ...
2009 NOV 23 ... of the oncogenic nuclear transcription factor c-Myc with aggressive behavior of many solid tumors. Therefore, this oncoprotein was evaluated as a prognostic marker for overall and ... stratified by c-Myc status and conventional prognostic factors (histological grade, tumor size, and tumor stage) were evaluated using standard univariate statistical methods. A ...
2009 NOV 23 ... in the anterior mediastinal area.""Histologically, the mass consisted of solid proliferation of neoplastic cells with spindle nuclei and cytoplasm and a few ... researchers concluded: "Oil the basis of these findings, this tumor was diagnosed as lymphoepithelial thymoma, which is morphologically similar to type A ...
2009 NOV 23 ... contact D.J. Adelstein, Cleveland Clinic, Taussig Cancer Institute, Dept. of Solid Tumor Oncology, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA. The ...
2009 NOV 23 ... In more than 30 countries, EGFRIs are currently used in the treatment of a number of solid tumors, and other indications are being sought." "In the United States, ... agents that act by inhibiting EGFR signaling transduction pathways, thus decreasing tumor growth. In more than 30 countries, EGFRIs are currently used in the treatment of a ...
2009 NOV 23 ... the entire series was 100%, 88.9% and 88.9% at 1, 3 and 5 years, respectively. Localized solid tumor progression was seen in two patients. Cyst progression was noted in three of nine ...
2009 NOV 23 ... is an anticancer nucleoside analogue active against a wide variety of solid tumors. However, following intravenous administration, this drug is rapidly inactivated ... higher anticancer activity compared with gemcitabine in an intravenously grafted tumor model in mice. To further establish the candidature of this nanomedicine for clinical ...
2009 NOV 23 ... months," said Philip Kantoff, M.D., chief clinical research officer, chief, division of solid tumor oncology, and director, Lank Center for Genitourinary Oncology at the Dana-Farber Cancer ...
2009 NOV 23 ... urine-based transrenal DNA/RNA technology which include assays to detect mutations in solid tumor cancers and organisms that cause infectious diseases. We will pursue a combined ...
